Citadel Advisors
KZR

Citadel Advisors’s Kezar Life Sciences KZR Stock Holding History

Citadel Advisors’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$117K Buy
+15,800
New +$103K ﹤0.01% 11879
2025
Q1 		– Sell
-800
Closed -$5.38K – 15094
2024
Q4 		$5.38K Buy
800
+740
+1,233% +$5.51K ﹤0.01% 13873
2024
Q3 		$464 Sell
60
-10
-14% -$60 ﹤0.01% 14014
2024
Q2 		$420 Buy
70
+10
+17% +$76 ﹤0.01% 13998
2024
Q1 		$541 Sell
60
-20
-25% -$182 ﹤0.01% 14317
2023
Q4 		$758 Sell
80
-2,860
-97% -$25.1K ﹤0.01% 13946
2023
Q3 		$35K Sell
2,940
-540
-16% -$9.57K ﹤0.01% 12149
2023
Q2 		$85.3K Buy
3,480
+2,720
+358% +$70.8K ﹤0.01% 11158
2023
Q1 		$23.8K Buy
760
+670
+744% +$38.8K ﹤0.01% 12926
2022
Q4 		$6.34K Sell
90
-2,130
-96% -$158K ﹤0.01% 13927
2022
Q3 		$191K Sell
2,220
-11,640
-84% -$1.13M ﹤0.01% 10447
2022
Q2 		$1.15M Buy
13,860
+9,390
+210% +$828K ﹤0.01% 6720
2022
Q1 		$743K Buy
+4,470
New +$642K ﹤0.01% 8422
2021
Q1 		– Sell
-1,330
Closed -$69K – 13489
2020
Q4 		$69K Buy
+1,330
New +$74K ﹤0.01% 10428

Other funds holding KZR

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RC
Rangeley Capital New Canaan, Connecticut $103M AUM 77.32% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Citadel Advisors's KZR Position: Q1 2026 in Review

Citadel Advisors opened a new position in Kezar Life Sciences (KZR) in Q1 2026: 59,403 shares worth $441K. The stake represents ﹤0.01% of the portfolio and ranks #9595 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in KZR as recently as Q3 2025.

Citadel Advisors first reported a position in KZR in Q1 2019 and has held it in 26 quarters since. The position peaked at $4.14M in Q1 2022. 43 funds tracked by Wall St. Rank hold KZR as of Q1 2026.

  • Citadel Advisors held 59,403 shares of Kezar Life Sciences worth $441K as of Q1 2026.
  • Kezar Life Sciences was a new Citadel Advisors position in Q1 2026.
  • Kezar Life Sciences made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #9595 holding.
  • Citadel Advisors first reported a position in Kezar Life Sciences in Q1 2019 and has held it in 26 quarters since.
  • Citadel Advisors's Kezar Life Sciences position peaked at $4.14M in Q1 2022.
  • 43 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.